Free tool
FAERS Monitor: Combigan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021398 or its brand name (Combigan, Brimonidine Tartrate, Timolol Maleate). Reports on generic versions are filed under their own applications.
Reports
6,644
Serious
2,704
41% of reports
Hospitalization
1,032
Death reported
318
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- ocular hyperaemia544
- eye irritation532
- eye pain481
- fatigue383
- drug ineffective365
- vision blurred341
- off label use297
- intraocular pressure increased295
- dizziness270
- eye pruritus255
- headache246
- diarrhoea215
- visual impairment211
- fall199
- death189
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 13 |
| 2008 | 40 |
| 2009 | 338 |
| 2010 | 193 |
| 2011 | 224 |
| 2012 | 158 |
| 2013 | 181 |
| 2014 | 213 |
| 2015 | 479 |
| 2016 | 695 |
| 2017 | 602 |
| 2018 | 611 |
| 2019 | 555 |
| 2020 | 561 |
| 2021 | 453 |
| 2022 | 369 |
| 2023 | 305 |
| 2024 | 257 |
| 2025 | 266 |
| 2026 | 128 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,515 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intraocular pressure increasedSignal | 295 | 74.8 | 66.8 | 20,918 |
| ocular hyperaemiaSignal | 544 | 36.7 | 33.8 | 18,680 |
| eye irritationSignal | 532 | 29.5 | 27.2 | 14,537 |
| eye painSignal | 481 | 27.2 | 25.0 | 12,048 |
| eye pruritusSignal | 255 | 24.2 | 21.4 | 5,615 |
| vision blurredSignal | 341 | 7.9 | 7.1 | 2,049 |
| visual impairmentSignal | 211 | 5.4 | 4.7 | 755 |
| fall | 199 | 1.9 | 1.7 | 84 |
| dizziness | 270 | 1.7 | 1.5 | 81 |
| fatigue | 383 | 1.6 | 1.4 | 79 |
| headache | 246 | 1.2 | 1.1 | 12 |
| off label use | 297 | 1.1 | 1.0 | 1 |
| diarrhoea | 215 | 1.1 | 0.9 | 1 |
| drug ineffective | 365 | 0.9 | 0.8 | 7 |
| death | 189 | 0.7 | 0.6 | 26 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.